Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

CME Group executive sells shares worth over $7,000

Published 03/22/2024, 04:06 PM
Updated 03/22/2024, 04:06 PM
© Reuters.

CME Group Inc. (NASDAQ:CME) Senior Managing Director and Global Head of Equity and FX, Timothy Francis McCourt, has recently sold a portion of his company shares, according to the latest filings. On January 31, McCourt sold 35 shares of CME Group's common stock at a price of $206.775, totaling over $7,000.

The transaction was labeled as delinquent, indicating it was reported later than the required timeframe. Following the sale, McCourt still holds a substantial number of shares in the company, with a total of 6,447 shares remaining in his possession.

Investors often monitor insider transactions as they can provide insights into how executives perceive the company's future prospects. However, such transactions are not always indicative of a company's long-term performance and can be influenced by various personal financial considerations.

CME Group, headquartered in Chicago, is a leading global financial market company offering the widest range of futures and options products for risk management. The company's shares are traded on the NASDAQ, and it is a critical component of the financial exchange industry.

InvestingPro Insights

As investors scrutinize the insider trading activity at CME Group Inc. (NASDAQ:CME), it's worth noting the broader financial metrics that paint a picture of the company's current market standing. CME Group's market capitalization stands at a robust $77.23 billion, underscoring its significant presence in the financial exchange industry. The company's commitment to shareholder returns is reflected in its consistent dividend track record, having raised its dividend for 5 consecutive years and maintaining dividend payments for 22 consecutive years.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

With a P/E ratio of 24.23 and a slightly higher adjusted P/E ratio for the last twelve months as of Q4 2023 at 24.27, the company trades at a premium relative to near-term earnings growth. This is further detailed in the PEG ratio of 1.22 for the same period, which investors might consider when assessing the stock's valuation against future earnings growth expectations. On the profitability front, analysts remain optimistic, predicting that the company will maintain profitability this year, a sentiment supported by CME Group's performance over the last twelve months.

For those looking to delve deeper into CME Group's financial health and future prospects, PRONEWS24 can be used to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. This platform offers a total of 7 additional InvestingPro Tips, including insights on earnings revisions by analysts and the company's long-term return profile.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.